Dose-context register / NO VALIDATED BLEND DOSE
BPC-157 TB-500 Dosage: What the Studies Administered, by Constituent
Read as research context, never as guidance: the doses below are what was given to which species by which route. There is no validated dose for the blend.
BPC-157 TB-500 dosage: research context, not guidance
BPC-157 TB-500 dosage has no validated value for the blend. Commercial research-product labelling commonly pairs the two peptides at fixed combined masses per vial — for example 10 mg + 10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists [8]. Everything below describes what was administered to which species by which route in the constituent literature. None of it is a human dosing recommendation.
For the BPC-157 component (animal models), rodent studies commonly express dose per body weight, frequently around 10 microg/kg and 10 ng/kg; gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats [1]. For the TB-500 / Thymosin Beta-4 component (animal models), the range is wide — for example 2-18 mg/kg intraperitoneal in a rat embolic-stroke dose-response study, where the modeled optimum was about 3.75 mg/kg and 18 mg/kg gave no benefit; higher was not better.
Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated to 1260 mg [5] and to 25 microg/kg single / 5 microg/kg-daily for 10 days [6]. Community "loading then maintenance" blend protocols have no controlled-trial basis.
What is the half-life of BPC-157 and TB-500?
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study. Human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses [5][6], but no specific half-life is established for the TB-500 heptapeptide.
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
In research handling, both peptides are supplied as lyophilized powders and reconstituted in bacteriostatic or sterile water, then refrigerated. A common community practice is to reconstitute the two separately or in a shared vial. This site does not provide volumes or administration instructions; note also that product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed.
How often should you inject BPC-157 and TB-500?
There is no validated injection frequency for the blend. The underlying rodent efficacy studies used intraperitoneal dosing schedules specific to each model [1][3], and the human data are single-agent intravenous Thymosin Beta-4 [5][6]. Community frequency protocols are not derived from controlled human trials and are not presented here as guidance.
How do you cycle BPC-157 and TB-500?
No controlled human trial defines a cycle for the blend. "Loading then maintenance" cycling is a community convention without a controlled-trial basis [8]. The constituent studies used fixed experimental schedules in animals, not cycles intended to translate to human use, so any cycling figure circulating online is extrapolation rather than evidence.
Bpc 157 tb 500 oral
Searches for bpc 157 tb 500 oral reflect interest in oral administration, and the constituent picture is uneven. BPC-157 is studied as a "stable gastric" peptide and has been administered perorally in animal research [1], which is why oral BPC-157 products are marketed. TB-500 / Thymosin Beta-4 is not characterized for oral use, and there is no validated oral pharmacokinetic profile for the blend.
The routes that actually appear in the studies are intraperitoneal (the predominant rodent efficacy route for both peptides), intravenous (the human Phase 1 route for full-length Thymosin Beta-4, and a BPC-157 safety pilot), and local or topical for individual-compound wound and tendon models [1][3][5][6]. Subcutaneous and intramuscular are the predominant research-community routes for the blend, but they appear in practice rather than in controlled human efficacy trials.
Routes and stability in the constituent research
Across the constituent literature, five routes appear, and they map to different evidence tiers. Intraperitoneal dosing is the predominant route in the underlying rodent efficacy studies for both peptides — it is where the BPC-157 transected-Achilles result [1] and the Thymosin-Beta-4 actin and migration work [3][4] were generated. Intravenous is the human route: full-length Thymosin Beta-4 was given intravenously in both Phase 1 trials [5][6], and BPC-157 was given intravenously in a small safety pilot. Local or intra-lesional and topical routes appear in individual-compound wound and tendon models, and the oral route is specific to BPC-157's gastric-stability research [1].
For handling, both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A common community practice is to reconstitute the two peptides separately or in a shared vial. The recurring caveat is that product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed — which compounds the existing identity gap on the TB-500 leg, where "TB-500" as sold is the Ac-LKKTETQ 7-mer while most efficacy data are for full-length Thymosin Beta-4 [4][7]. None of this is administration guidance; it describes what the research record and the supply form actually are.
Why there is no validated blend dose
Three facts close the question of a "correct" Wolverine dose, and all three point the same way. First, no peer-reviewed combination dose-finding study exists for BPC-157 + TB-500 — there is no published ratio, dose, or endpoint for the two given together [8]. Second, the dose-response data that do exist for the constituents are not monotonic: in a rat embolic-stroke study, Thymosin Beta-4 at 18 mg/kg gave no benefit while the modeled optimum sat near 3.75 mg/kg, so "more is better" loading logic is contradicted by the animal data. Third, the human reference points are single-agent and for the parent protein, not the fragment or the blend — full-length Thymosin Beta-4 tolerated to 1260 mg intravenously [5] and to 25 microg/kg single / 5 microg/kg-daily [6].
Community "loading then maintenance" protocols and fixed-ratio vials such as 10 mg + 10 mg are product and forum conventions, not validated dosing [8]. This terminal posts the research doses as what they are — figures administered to specific species by specific routes in specific studies — and leaves the blend dose row open, because the literature does.